Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000688200.74686.e6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
UPLC Estimate of Sofosbuvir and Ledipasvir Utilizing Greenness Tool in Conjunction With an Analytical Quality by Design.
Biomed Chromatogr
January 2025
Department of Pharmaceutical Analysis, Srikrupa Institute of Pharmaceutical Sciences, Siddipet, India.
Ledipasvir in combination with sofosbuvir approved by regulatory bodies used to treat chronic hepatitis C. The present work investigates the design and development of a new, quick, green, and selective UPLC (ultra-performance liquid chromatography) approach to concurrently quantify sofosbuvir and ledipasvir. Optimization with Box-Behnken design paired the green analytical method and quality by design-based risk assessment.
View Article and Find Full Text PDFValidation of spectrophotometric and colorimetric method for the specific quantification of sofosbuvir From luminar capsule microneedle in liver tissue through ex vivo and in vivo applications.
Ann Pharm Fr
November 2024
Faculty of Pharmacy, Hasanuddin University, Makassar, 90245 South Sulawesi, Indonesia. Electronic address:
An antiviral prodrug that has received regulatory approval and primarily employed in the treatment of hepatitis C is sofosbuvir (SOF). It is therefore imperative to develop advanced delivery methods for SOF in order to address existing absor ption issue and maximize the efficacy. In this study, we developed microneedle-integrated SOF (MN-SOF) which were elongated with branches and coated capsules to form luminar capsule microneedles (LUCAMs).
View Article and Find Full Text PDFReal-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy.
Infection
November 2024
Gemeinschaftspraxis Am Kaiserplatz, Bonn, Germany.
Article Synopsis
- HCV treatment has significantly improved with direct-acting antiviral therapy (DAA), allowing for shorter treatment durations and better tolerability in difficult-to-treat populations, such as people who inject drugs (PWID) and those on opioid substitution therapy (OST).
- A retrospective analysis of patients receiving DAA at a clinic in Bonn showed that all patients on glecaprevir/pibrentasvir completed their treatment, while 86% of those on sofosbuvir/velpatasvir did, resulting in a 74% sustained virological response (SVR) overall, despite some patients being lost to follow-up.
- The study highlights high adherence and SVR rates for HCV treatment in PWID, supporting efforts to
Ligand-Enabled Cu-Catalyzed Stereoselective Synthesis of P-Stereogenic ProTides.
J Am Chem Soc
November 2024
Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai 200240, China.
Nucleoside analogues have seen significant advancements in treating viral infections and cancer through ProTide technology, leading to a series of FDA-approved drugs such as sofosbuvir, tenofovir alafenamide, and remdesivir. The stereochemical configuration at the phosphorus center of ProTides significantly influences their pharmacological properties, necessitating efficient stereoselective synthesis. Traditional methods using chiral auxiliaries or nonracemic phosphorylating agents are labor-intensive and inefficient, while recent organocatalytic approaches, despite their promise, still face limitations.
View Article and Find Full Text PDFRescue therapy with Sofosbuvir /Velpatasvir/ Voxilaprevir in a patient infected with Hepatitis C virus multidrug resistant variant-a much needed option for DAA-treatment failures in Pakistan? A case-report.
J Pak Med Assoc
October 2024
Department of Gastroenterology, Private Clinic, Karachi, Pakistan.
Primary non-response to the currently available direct acting anti-viral (DAAs) in chronic hepatitis C virus (HCV) is rare and expected in approximately only 3-4% of the patients. Among the plausible explanations, HCV resistant variant may be one of the causes among the several other viral and host factors implicated in cases who do not achieve cure. Ever since the approval of licensed DAAs in 2014, focus has been mainly on high cure rates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!